Sept 24 (Reuters) - Harmony Biosciences (HRMY.O), opens new tab said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback